Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.42 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.42 |
| ▸ | CDC25B | P30305 | 5/20 | 0.42 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181126 | 1.00 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL181077 | 1.00 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL181127 | 1.00 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL16581477 | 1.00 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL6929599 | 1.00 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL9853879 | 0.96 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL9853878 | 0.96 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL1776774 | 0.95 | SLC6A2 (0.47) | SLC6A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL13224920 | 0.90 | SLC6A2 (0.56) | SLC6A2BCHE | |
| SCHEMBL2536430 | 0.90 | SLC6A2 (0.56) | SLC6A2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627691-B1 | DEGRADABLE POLYCARBONATES | TEXAS A&M UNIV (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10052373-B2 | Protein and peptide-free synthetic vaccines against Streptococcus pneumoniae type 3 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-08-21 | — | — | US | disclosed |
| EP-3046587-B1 | PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS (DE) | 2018-01-31 | — | — | EP | disclosed |
| US-20160279224-A1 | PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-09-29 | — | — | US | disclosed |
| EP-2851092-A1 | Protein and peptide-free synthetic vaccines against streptococcus pneumoniae type 3 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2627691-A1 | DEGRADABLE POLYCARBONATES | Texas A&M University (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012051448-A1 | DEGRADABLE POLYCARBONATES | TEXAS A&M UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
| EP-2388264-A1 | COMPOUND RETAINED IN TUMOR | Toyo Suisan Kaisha, Ltd. (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20110254443-A1 | PHASE AND FREQUENCY LOCKED MAGNETRON | MUONS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-7973145-B2 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100298246-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100298246-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100202971-A1 | COMPOUND HAVING TUMOR-RESIDENT PROPERTY | OHTA KEISUKE | 2010-08-12 | — | — | US | disclosed |
| EP-2130834-A1 | NOVEL SULFONATED SUGAR DERIVATIVE, AND USE THEREOF FOR MEDICINAL AGENT | Toyo Suisan Kaisha, Ltd. (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20090209475-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090209475-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | TOYO SUISAN KAISHA, LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-0642799-B1 | Improved prodrugs for enzyme mediated activation | HOECHST AG (DE) | 2001-11-07 | — | — | EP | disclosed |
| US-5621002-A | HAVING A MODIFIED COMPETITIVE ENZYME ACTIVITY INHBITOR LINKED TO A SPACER-DRUG; ENZYME CLEAVAGE AT A LOWER CONCENTRATION, I.E. LOW MICHAELIS-MENTEN CONSTANT(KM) | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | disclosed |
| EP-0642799-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | disclosed |
| US-4818816-A | ANTICOAGULANT | CHOAY, S.A. (FR) | 1989-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298246-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | SLC5A2, SLC5A1, DEGS1 | SLC6A2 2314/4885SSTR1 820/4885SSTR2 521/4885 |
| US-10052373-B2 | Protein and peptide-free synthetic vaccines against Streptococcus pneumoniae type 3 | STT3A, DDOST, LGALS3BP | SLC6A2 4364/4885SSTR1 1795/4885SSTR2 1874/4885 |
| US-20100202971-A1 | COMPOUND HAVING TUMOR-RESIDENT PROPERTY | HRH3, HRH4, HNRNPH3 | SLC6A2 2975/4885SSTR1 417/4885SSTR2 529/4885 |
| US-20090209475-A1 | Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same | SLC5A2, SLC5A1, DEGS1 | SLC6A2 2314/4885SSTR1 820/4885SSTR2 521/4885 |
| US-20160279224-A1 | PROTEIN AND PEPTIDE-FREE SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE TYPE 3 | STT3A, DDOST, LGALS3BP | SLC6A2 4364/4885SSTR1 1795/4885SSTR2 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.